Where you inject matters: new study tests insulin at three sites
NCT ID NCT07257627
First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This completed Phase 1 study looked at how a single dose of the insulin drug THDB0206 behaves when injected into the upper arm, abdomen, or thigh. Twenty-seven healthy Chinese adults each received the same dose at all three sites in a random order. The goal was to see if the injection site changes how fast and how much insulin enters the blood and how it affects blood sugar levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital of Sichuan University
Sichuan, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
THDB0206 (insulin lispro)
What this could lead to
If successful, this study could help determine the best injection site for THDB0206, potentially improving how quickly and consistently the insulin works.
What could go wrong
This is a very early Phase 1 study in only 27 healthy people, so results may not apply to patients with diabetes. The study is already completed, so no new data is expected.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.